New Test Achieves Over 90% Accuracy in Predicting Bowel Cancer Risk for IBD Patients

The UK-developed algorithm could lead to a blood test, helping high-risk patients with Crohn's and colitis manage their cancer risk more effectively.

Researchers at the Institute of Cancer Research (ICR) in the UK have developed a test that predicts bowel cancer risk with over 90% accuracy in patients with inflammatory bowel disease (IBD).
The algorithm analyzes DNA changes in pre-cancerous cells to identify individuals most likely to develop bowel cancer within five years.
The test aims to reduce the need for frequent colonoscopies and unnecessary surgeries by providing personalized risk assessments for patients with Crohn's disease and ulcerative colitis.
Scientists hope to translate this research into a simple blood test, making early detection and intervention more accessible in clinical settings.
The study, funded by Cancer Research UK, highlights the potential for cost savings in healthcare and improved quality of life for patients by focusing resources on those at highest risk.